Lantern Pharma INC

Lantern Pharma announced second quarter 2026 financial results, detailing progress in its oncology drug pipeline, including LP-300 and LP-184, and the establishment of Open Medicine AI as a separate entity.

Lantern Pharma establishes Open-Medicine AI as a separate entity to commercialize its multi-agent AI co-scientist platform, expanding beyond oncology.

Lantern Pharma has closed a $4.4 million registered direct offering and concurrent private placement to fund working capital and general corporate purposes.

Lantern Pharma presented its multi-agentic AI co-scientist platform, withZeta.ai, highlighting its capabilities in rare cancer drug discovery and clinical trial design.

Lantern Pharma announced its Q4 and full-year 2025 financial results, highlighting clinical validation across multiple oncology programs and the commercialization progress of its AI platforms.

Lantern Pharma Inc. announced the demonstration of its initial AI tools and multi-agentic system focused on rare cancers at a company-hosted event.

Lantern Pharma reported a net loss of $10.4 million for the first six months of 2026, highlighting substantial doubt about its ability to continue as a going concern without significant additional funding.

Lantern Pharma reports Q1 2026 financial results and announces plans to spin off its withZeta.ai platform into an independent entity.

Lantern Pharma reported a narrower net loss in Q3 2025 and advanced its drug pipeline, but faces a going concern risk and requires substantial additional funding.

Lantern Pharma Inc. reported a reduced net loss in Q2 2025 but faces substantial doubt about its ability to continue as a going concern due to significant cash burn and declining liquidity.

Lantern Pharma Inc. announces its Q1 2025 financial results, emphasizing the continued advancement of its AI-driven RADR platform and clinical programs.

Lantern Pharma reported a net loss of $4.5 million for the third quarter of 2024, while advancing its clinical programs and research initiatives.

Lantern Pharma Inc. has filed an amendment to its 2025 Form 10-K, primarily to include previously omitted information regarding directors, executive officers, and corporate governance.

Lantern Pharma, an AI-driven oncology firm, reported continued net losses in 2025 and faces substantial doubt about its ability to continue as a going concern, despite advancing multiple drug candidates and expanding its AI platform.

Lantern Pharma files an amendment to its 2024 Annual Report on Form 10-K to include previously omitted information regarding directors, executive officers, and corporate governance.

Lantern Pharma Inc. outlines its progress in AI-driven oncology drug development and reports its financial results for the fiscal year ended December 31, 2024.

Lantern Pharma's 2023 annual report highlights its focus on leveraging AI and genomic data to advance its oncology drug pipeline, including clinical trials for LP-300, LP-184, and LP-284.

Lantern Pharma Inc. Director D. Jeffrey Keyser acquired 53,844 stock options with an exercise price of $3.49, vesting over 12 and 24 months.

Lantern Pharma Inc. Director Maria-Luisa Maccecchini was granted 46,152 stock options with an exercise price of $3.49, vesting over 12 and 24 months.

Lantern Pharma Inc. Director Vijay Chandru was granted 42,307 stock options with an exercise price of $3.49, vesting over 12 and 24 months.

Lantern Pharma Inc. director Lee Troy Schalop was granted 43,460 stock options at an exercise price of $3.49, vesting over 12 and 24 months.

Lantern Pharma Inc. Director David S. Silberstein was granted 42,307 stock options with an exercise price of $3.49, vesting over 12 and 24 months.

Lantern Pharma Inc.'s Chief Financial Officer, David R. Margrave, was granted 20,000 stock options with an exercise price of $3.24 per share.

Lantern Pharma Inc. will hold its 2025 Annual Meeting to vote on director elections, a one-time stock option repricing, auditor ratification, and meeting adjournment.

Lantern Pharma is asking stockholders to approve an amendment to its equity incentive plan to increase the number of shares available for issuance by 125,000.

Bios Equity Partners and associated entities have filed an amendment to their Schedule 13D regarding their beneficial ownership in Lantern Pharma Inc.

Bios Capital Management and related entities report a combined 8.58% beneficial ownership in Lantern Pharma Inc. common stock.

A group of investment entities and individuals, including Bios Equity Partners and Cavu Management, have significantly reduced their beneficial ownership in Lantern Pharma Inc. through a series of open market sales.

Empery Asset Management, LP and Ryan M. Lane have filed a Schedule 13G, reporting beneficial ownership of 9.99% of Lantern Pharma Inc.'s common stock, including shares issuable from warrants.

Thomas A. Satterfield, Jr. has reported beneficial ownership of 975,000 shares, representing 7.6% of Lantern Pharma Inc.'s common stock.

Thomas A. Satterfield, Jr. has disclosed beneficial ownership of 570,000 shares, representing 5.1% of Lantern Pharma Inc.'s common stock, as of March 30, 2026.